The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact

For those diagnosed with early-stage HR , HER2- #BreastCancer, the Oncotype DX Breast Recurrence Score® test means more than predicting whether they are likely to benefit from #chemotherapy.* It can mark an emotional turning point in the #CancerJourney. Learn more: http://spr.ly/61894MmRU recurrence-score-patients *Albain et al. Lancet Oncol. 2010;11(1):55-65; Paik et al. J Clin Oncol. 2006;24(24):3726-3734 | Until Everyone Knows

PUT CHEMO TO THE TEST. Oncotype DX® is the only test that knows if chemo is needed for early-stage breast cancer. | Until Everyone Knows

Every person’s breast cancer experience is different, but there’s one thing that could help anyone facing a diagnosis: answers. Over the past 20 years, the Oncotype DX® test has empowered breast cancer patients to make more informed, personalized treatment decisions. #20YearsofOncotypeDX #BreastCancerAwarenessMonth | Exact Sciences